Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 10.45 Million CHF | -13.96% |
| 2022 | 12.14 Million CHF | 277.82% |
| 2021 | -6.83 Million CHF | 53.6% |
| 2020 | -14.72 Million CHF | 34.34% |
| 2019 | -22.42 Million CHF | 28.48% |
| 2018 | -31.35 Million CHF | -61.94% |
| 2017 | -19.36 Million CHF | 62.25% |
| 2016 | -51.28 Million CHF | 16.75% |
| 2015 | -61.6 Million CHF | -48.28% |
| 2014 | -41.54 Million CHF | -25.82% |
| 2013 | -33.01 Million CHF | 37.74% |
| 2012 | -53.03 Million CHF | 8.0% |
| 2011 | -57.64 Million CHF | -153.59% |
| 2010 | 107.56 Million CHF | 189.09% |
| 2009 | -120.73 Million CHF | 15.88% |
| 2008 | -143.52 Million CHF | -13.18% |
| 2007 | -126.81 Million CHF | -48.94% |
| 2006 | -85.14 Million CHF | -71.69% |
| 2005 | -49.59 Million CHF | 34.29% |
| 2004 | -75.47 Million CHF | -35.62% |
| 2003 | -55.65 Million CHF | 5.63% |
| 2002 | -58.97 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 20.73 Million CHF | 0.0% |
| 2023 Q4 | -21.38 Million CHF | 0.0% |
| 2023 Q2 | 31.84 Million CHF | 0.0% |
| 2023 FY | 10.45 Million CHF | -13.96% |
| 2022 Q4 | 24.35 Million CHF | 0.0% |
| 2022 Q2 | -12.2 Million CHF | 0.0% |
| 2022 FY | 12.14 Million CHF | 277.82% |
| 2021 Q2 | -19.89 Million CHF | 0.0% |
| 2021 Q4 | 13.06 Million CHF | 0.0% |
| 2021 FY | -6.83 Million CHF | 53.6% |
| 2020 Q2 | 9.94 Million CHF | 0.0% |
| 2020 FY | -14.72 Million CHF | 34.34% |
| 2020 Q4 | -24.66 Million CHF | 0.0% |
| 2019 Q4 | -6.99 Million CHF | 0.0% |
| 2019 Q2 | -15.43 Million CHF | 0.0% |
| 2019 FY | -22.42 Million CHF | 28.48% |
| 2018 FY | -31.35 Million CHF | -61.94% |
| 2018 Q2 | -22.54 Million CHF | 0.0% |
| 2018 Q4 | -8.8 Million CHF | 0.0% |
| 2017 Q2 | -20.56 Million CHF | 0.0% |
| 2017 Q4 | 1.2 Million CHF | 0.0% |
| 2017 FY | -19.36 Million CHF | 62.25% |
| 2016 Q2 | -27.92 Million CHF | 0.0% |
| 2016 FY | -51.28 Million CHF | 16.75% |
| 2016 Q4 | -23.36 Million CHF | 0.0% |
| 2015 Q2 | -30.11 Million CHF | 0.0% |
| 2015 Q4 | -31.48 Million CHF | 0.0% |
| 2015 FY | -61.6 Million CHF | -48.28% |
| 2014 Q4 | -22.11 Million CHF | 0.0% |
| 2014 FY | -41.54 Million CHF | -25.82% |
| 2014 Q2 | -19.43 Million CHF | 0.0% |
| 2013 Q4 | -15.73 Million CHF | 0.0% |
| 2013 Q2 | -17.28 Million CHF | 0.0% |
| 2013 FY | -33.01 Million CHF | 37.74% |
| 2012 Q2 | -13.25 Million CHF | 0.0% |
| 2012 Q1 | -13.25 Million CHF | 0.0% |
| 2012 Q4 | -8.25 Million CHF | 37.74% |
| 2012 FY | -53.03 Million CHF | 8.0% |
| 2012 Q3 | -13.25 Million CHF | 0.0% |
| 2011 FY | -57.64 Million CHF | -153.59% |
| 2011 Q3 | -14.41 Million CHF | 0.0% |
| 2011 Q4 | -13.25 Million CHF | 8.0% |
| 2011 Q2 | -14.41 Million CHF | 0.0% |
| 2011 Q1 | -14.41 Million CHF | 0.0% |
| 2010 Q4 | -14.41 Million CHF | -153.59% |
| 2010 FY | 107.56 Million CHF | 189.09% |
| 2010 Q2 | 26.89 Million CHF | 0.0% |
| 2010 Q1 | 26.89 Million CHF | 0.0% |
| 2010 Q3 | 26.89 Million CHF | 0.0% |
| 2009 FY | -120.73 Million CHF | 15.88% |
| 2009 Q1 | -30.18 Million CHF | 0.0% |
| 2009 Q2 | -30.18 Million CHF | 0.0% |
| 2009 Q3 | -30.18 Million CHF | 0.0% |
| 2009 Q4 | 26.89 Million CHF | 189.09% |
| 2008 FY | -143.52 Million CHF | -13.18% |
| 2008 Q4 | -30.18 Million CHF | 15.88% |
| 2008 Q1 | -35.88 Million CHF | 0.0% |
| 2008 Q2 | -35.88 Million CHF | 0.0% |
| 2008 Q3 | -35.88 Million CHF | 0.0% |
| 2007 Q2 | -31.7 Million CHF | 0.0% |
| 2007 Q4 | -35.88 Million CHF | -13.18% |
| 2007 Q3 | -31.7 Million CHF | 0.0% |
| 2007 Q1 | -31.7 Million CHF | 0.0% |
| 2007 FY | -126.81 Million CHF | -48.94% |
| 2006 Q2 | -21.28 Million CHF | 0.0% |
| 2006 Q3 | -21.28 Million CHF | 0.0% |
| 2006 Q4 | -31.7 Million CHF | -48.94% |
| 2006 FY | -85.14 Million CHF | -71.69% |
| 2006 Q1 | -21.28 Million CHF | 0.0% |
| 2005 Q4 | -21.28 Million CHF | -71.14% |
| 2005 Q3 | -12.43 Million CHF | 0.0% |
| 2005 Q1 | -12.43 Million CHF | 0.0% |
| 2005 Q2 | -12.43 Million CHF | 0.0% |
| 2005 FY | -49.59 Million CHF | 34.29% |
| 2004 FY | -75.47 Million CHF | -35.62% |
| 2004 Q1 | -18.86 Million CHF | 0.0% |
| 2004 Q2 | -18.86 Million CHF | 0.0% |
| 2004 Q3 | -18.86 Million CHF | 0.0% |
| 2004 Q4 | -12.43 Million CHF | 34.08% |
| 2003 Q1 | -13.91 Million CHF | 0.0% |
| 2003 Q3 | -13.91 Million CHF | 0.0% |
| 2003 Q4 | -18.86 Million CHF | -35.62% |
| 2003 Q2 | -13.91 Million CHF | 0.0% |
| 2003 FY | -55.65 Million CHF | 5.63% |
| 2002 Q3 | -14.74 Million CHF | 0.0% |
| 2002 FY | -58.97 Million CHF | 0.0% |
| 2002 Q2 | -14.74 Million CHF | 0.0% |
| 2002 Q1 | -14.74 Million CHF | 0.0% |
| 2002 Q4 | -13.91 Million CHF | 5.63% |
| 2001 Q4 | -14.74 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | 199.003% |
| BB Biotech AG | -206.6 Million CHF | 105.058% |
| Evolva Holding SA | -105.22 Million CHF | 109.932% |
| Idorsia Ltd | -297.92 Million CHF | 103.508% |
| Kuros Biosciences AG | -13.72 Million CHF | 176.135% |
| Molecular Partners AG | -61.98 Million CHF | 116.861% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | 110.645% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 80.923% |